

Danish Healthcare & Life Science Export Promotion

With the participation of Ida Auken, Minister for Health & Minister for Ecclesiastical Affairs of Denmark

Beijing & Greater Bay Area

22–26 February 2027

DANSK ERHVERV
Danish Chamber of Commerce

EMBASSY OF THE KINGDOM OF DENMARK
Beijing

CONSULATE GENERAL OF DENMARK
Guangzhou

Danish Industry

Healthcare Denmark

Invitation

The Embassy of the Kingdom of Denmark in Beijng, The Consulate General of Denmark in Guangzhou, together with the Danish Chamber of Commerce, Confederation of Danish Industry and Healthcare Denmark are pleased to invite you to participate in an upcoming health and life sciences delegation visit to the Beijing and Greater Bay Area (Shenzhen and Hong Kong) from 22 – 26 February 2027 with high-level participation from the Minister for Health & Minister of Ecclesiastical Affairs of Denmark.

The Greater Bay Area (GBA) is a national development initiative encompassing Hong Kong, Macao and nine major cities, each with over a million inhabitants, in the large southern Chinese province of Guangdong. It brings together one of China's most dynamic regions, with more than 87 million inhabitants and some of the world's leading innovation ecosystems and technology companies. The GBA aims to integrate manufacturing, research and technological development into one interconnected region, while improving the business environment and framework conditions, particularly by strengthening links between Hong Kong and mainland China.

The GBA initiative is driven by economic integration and regulatory harmonisation, with life sciences as a particular priority. Pilot schemes seek to introduce elements of Hong Kong's outstanding healthcare system and more flexible regulatory framework into Guangdong province. Danish life science companies are already benefiting from the more favourable conditions created by the initiative.

Within the GBA, Hong Kong is particularly attractive—not only as an international financial and business hub offering straightforward market access and excellent business conditions, but also, from a healthcare perspective, because of its independent healthcare system with its own regulatory processes and frameworks. Its publicly funded healthcare system is of a high standard, and health outcomes and living standards in the city are among the highest in the world. Hong Kong is also introducing measures to improve its regulatory framework, including for medicine approvals, clinical trials and data, as well as streamlining approval processes for medical devices. These developments also create opportunities for Danish companies.

Joining this delegation will give Danish companies a insightful combination of the understanding the political development and priorities within life science and healthcare, gain insight and learn about market opportunities in Southern China through Hong Kong.

Life science research and development in southern China, along with the GBA's pilot initiatives for life science collaboration—including more flexible rules on cross-border clinical trials and data exchange—take place in locations such as the Hetao development zone, a joint innovation and research area on the border between Hong Kong and Shenzhen in mainland China. For Danish companies, this makes Hong Kong and Shenzhen ideal locations for gaining insight into new market opportunities and regulatory developments in China's life science sector.

Why join

- Understand potential and impact of Chinas 15th 5-year plan, whilst engaging with high-level Danish and Chinese stakeholders.
- Get a look into cutting-edge developments in AI and digital health, including how AI is transforming diagnostics, clinical research, hospital management and patient care.
- Gain insight into emerging Chinese competitors, potential partners and technological developments in the Greater Bay Area (GBA), while gaining insight into a major global growth hub for health and life sciences.
- Establish contacts and engage in dialogue with local healthcare stakeholders, including public authorities, with a focus on regulatory frameworks, and local companies with cutting-edge technological expertise seeking partnerships with leading Danish life science companies.
- Showcase your companies' products and solutions to relevant procurement departments at local hospitals, within the public healthcare system and at private companies based in Hong Kong and Shenzhen.

Price: 25.125 DKK
The participation fee is indicative and based on an assumption of the eventual number of participating companies. The exact and final participation fee will be communicated to all signed up companies, as soon as the deadline for sign-up has expired. However, we expect the price to be very close to 25,000 DKK *(this does not include accomodation and flight from Denmark and in China)*

Contact

Please advise your interest and opportunity to partake by replying to Sara Vogt Bøgsted, sabo@danskerhverv.dk (DE) and Oliver Bramsted, olbr@di.dk (DI). For any programme related questions please contact Jane Cen from The Consulate General of Denmark in Guangzhou on jancen@um.dk.

Program

Please note that the programme is tentative and subject to change.

Day 1 / Sunday 21/2, Beijing

18:00

Flight CA878 Departure from Kastrup Airport
Transfer to hotel

Day 2 / Monday 22.02, Beijing

09:40

Flight CA878 arrival at Beijing Capital Airport

12:00-13.00

Lunch with the Minister for Health and the Minister for Ecclesiastical Affairs

Informal lunch and exchange on the programme ahead, key developments in China's healthcare and life science sector, and Danish priorities for the visit.

13.00-14.00

High-Level Seminar: The Future of Healthcare in China – Policy, Innovation and AI Seminar

Bringing together senior decision-makers, healthcare experts and industry leaders to provide the delegation with an outlook on the Chinese healthcare market. Particular focus will be placed on the implications of China's new 15th Five-Year Plan (2026–2030) for healthcare and life sciences, including expected policy priorities, market developments and opportunities for international cooperation. A second focus will be on cutting-edge developments in AI and digital health, including how AI is transforming diagnostics, clinical research, hospital management and patient care.

14.00-15.00

Keynote: China's Healthcare Market under the 15th Five-Year Plan

A keynote address by a prominent expert on China's healthcare sector, offering strategic insights into how China's 15th Five-Year Plan (2026–2030) will shape the future of healthcare and life sciences. The session will explore key policy and market developments, including healthcare reform, innovation, AI and digital health, with particular emphasis on emerging opportunities and strategic implications for international companies operating in China.

Program

Day 3 / Tuesday 23.02, Shenzhen

Evening/early morning day 3
Flight to Shenzhen

09.00-10.30

Meeting and tour at BAY TRIAL - Greater Bay Area International Clinical Trials Center (Shenzhen side)

The National Health and Medical Big Data Research Institute (Shenzhen) was established in November 2020 with the approval of the Planning and Information Technology Department of the National Health Commission. The visit will offer first-hand insights into one of the GBA's emerging clinical research platforms and its role in connecting research institutions, hospitals and industry. Through presentations and a guided tour, the delegation will explore how clinical trials are organised and conducted in China, including opportunities for international collaboration, testing and validation of new medical technologies. Particular attention will be given to the practical opportunities and challenges facing international companies seeking to conduct clinical research, collaborate with Chinese partners and bring innovative healthcare solutions to the Chinese market.

10.30-12.00

Visit to a Chinese life science health tech company #1 using trials applications at BAY TRIAL, or visit to The National Health and Medical Big Data Research Institute (Shenzhen)

The National Health and Medical Big Data Research Institute (Shenzhen) was established in November 2020 with the approval of the Planning and Information Technology Department of the National Health Commission.

Perspectives on China's 15th Five-Year Plan with focus on Implications for Healthcare, Innovation and Market Access could be shared from this visit

The keynote will provide an overview of how the priorities of China's 15th Five-Year Plan are expected to influence the healthcare and life sciences sectors. It will focus on China's ambitions to strengthen healthcare resilience, promote domestic innovation, address demographic changes and develop strategic industries such as biotechnology, medical technology and digital health.
The presentation will also consider the implications for Danish companies in terms of reciprocal market access, regulation, investment and opportunities for cooperation.

Program

Day 3 / Tuesday 23.02, Shenzhen

13.30-15.30

Visit Chinese life science company #2, iCarbonX

iCarbonX is a Shenzhen-headquartered global digital health unicorn, dedicated to building AI-powered multi-omics platforms that integrate genomics, proteomics, metabolomics, microbiome, and lifestyle data to create comprehensive digital human profiles and drive precision health. Key points below will be addressed during the visit:

- How Chinese companies develop and commercialise innovative technologies
- How iCarbonX's growth ambitions and its position in China, Europe and global markets
- What increasing Chinese innovation and market competition mean for Danish and other international companies

---

16.30-18.00

Visit at LINAK (Shenzhen) Actuator Systems Co., Ltd. China Headquarter

LINAK (Shenzhen) Actuator Systems, established in April 2005 as the wholly foreign-owned subsidiary of Denmark's LINAK Group, is a core Danish industrial and healthcare tech company in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA). Operating from its China headquarter in Shenzhen, in May 2026 LINAK established a new, expanded factory in Dongguan north of Shenzhen with over 200 employees, serving as LINAK's key APAC base for production, R&D, sales, and logistics.

- Building a competitive production and business platform in China
Perspectives from LINAK (Shenzhen) Actuator Systems Co., Ltd

- How LINAK has developed its production and sales operations in China
- The benefits and challenges of producing locally
- Cooperation with Chinese suppliers, customers and other stakeholders
- How the company manages changing regulatory, market and competitive conditions
- LINAK's role and future development in China, as well as its contribution to the company's global competitiveness

---

18.30-20.30

Business networking event at the hotel; Danish business community and Chinese stakeholders within the Healthcare & Life science sector including potential participation from National Medical Products Administration (NMPA) and other important stakeholders

Program

Day 4 / Wednesday 24.02, Shenzhen - Hong Kong

Cross the Shenzhen – Hong Kong border

09.00-12.00

Visit Greater Bay Area International Clinical Trial Institute (GBAICTI)

Venue 1: Temporary Office of GBAICTI, Greater Bay Area International Clinical Trial Institute

GBAICTI is Hong Kong's flagship international clinical trial institute, wholly owned by the HKSAR Government and operated by the University of Hong Kong's LKS Faculty of Medicine. Launched in November 2024 at the Hetao Shenzhen-Hong Kong Innovation Zone, it serves as the global gateway for GBA clinical research, leveraging Hong Kong's unparalleled international connectivity, top-tier medical talent, and world-class regulatory alignment.

A state-of-the-art one-stop platform, it coordinates public-private healthcare resources and houses a 400,000+ sample biobank (tissues, blood, cells, DNA) with advanced cryogenic storage. It accelerates cross-border multi-center trials meeting both Chinese and international standards, driving Hong Kong's rise as a global biomedical innovation hub via real-world data integration and global collaboration frameworks.

Venue 2: Hong Kong Park, Hong Kong-Shenzhen Innovation and Technology Park (HSITP)

Perspectives on the first five-year plan for Hongkong; with focus on addressing Hongkong's priorities within healthcare sector

13.00-14.30

Meeting with the Secretary of Health/Health Bureau, Hongkong; Medical products regulation division covering drug and medical device

15.30-18.00

Hospital Visit including a meeting with Hospital Authority at Prince of Wales Hospital (PWH)

Prince of Wales Hospital (PWH) is a flagship regional acute hospital under Hong Kong's Hospital Authority. Hospital Authority - Established in 1990 and operational since December 1991, the Hospital Authority is Hong Kong's statutory body managing all public hospitals and healthcare services. Overseen by the Hong Kong SAR Government via the Secretary for Health, it operates as the backbone of Hong Kong's public healthcare system, delivering comprehensive, affordable care to residents.

HA offers a full spectrum of services including inpatient, emergency, specialist and general outpatient care, rehabilitation, and community outreach. It drives smart hospital transformation through digital health initiatives, supports medical education and research, and maintains a strong focus on patient-centered care, professionalism, and service quality.

Program

Day 4 / Wednesday 24.02, Shenzhen - Hong Kong

18.30

Check-in Hotel Kowloon Shangri-la

19.30

A potential Business network event with Hong Kong Obesity Society, Hongkong allergy society Hong Kong Public Doctors' Association, Pharmaceutical Society of Hong Kong, Health Tech authorities

Day 5 / Thursday 25.02, Hong Kong

09.00-11.00

Visit at Hong Kong Centre for Medical Products Regulation (CMPR)

It will implement the Primary Evaluation framework to enable independent approval of drugs and medical devices based on local clinical evidence. CMPR will introduce a mandatory registration system for medical devices and strengthen pre-market and post-market controls. Hong Kong is actively pursuing ICH membership (International Council for Harmonisation, the global body setting unified pharmaceutical safety, efficacy and quality standards), to align local regulation with international best practice. Positioned as a key GBA-global regulatory bridge, CMPR provides Danish healthcare partners with a compliant, efficient gateway for clinical validation, medtech registration and cross-border innovation.

12.00-15.00

Seminar and working lunch

Doing Healthcare & Life Science Business in Greater Bay Area" with perspectives shared by Danish companies present in China e.g. Lundbeck Hongkong, Novo Nordisk Hongkong, and ALK.

China's growing innovative capacity and Chinese companies' increasing market shares - and what these developments mean for the long-term competitiveness of Danish companies in GBA, China, Europe and globally.

Day 6 / Friday 26.02, Hongkong – Copenhagen

Departure from Hongkong to Copenhagen